WallStSmart

Alibaba Group Holding Ltd (BABA)vsBrilliA Inc (BRIA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 1662701% more annual revenue ($1.02T vs $61.56M). BABA leads profitability with a 10.1% profit margin vs 2.8%. BABA trades at a lower P/E of 17.3x. BABA earns a higher WallStSmart Score of 64/100 (C+).

BABA

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 5.0Value: 9.3Quality: 6.5
Piotroski: 2/9Altman Z: 2.02

BRIA

Avoid

32

out of 100

Grade: F

Growth: 2.0Profit: 5.5Value: 5.3Quality: 8.0
Piotroski: 4/9Altman Z: 5.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BABAUndervalued (+60.2%)

Margin of Safety

+60.2%

Fair Value

$382.49

Current Price

$121.06

$261.43 discount

UndervaluedFair: $382.49Overvalued

Intrinsic value data unavailable for BRIA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BABA6 strengths · Avg: 9.2/10
Market CapQuality
$270.36B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.3910/10

Growing faster than its price suggests

EPS GrowthGrowth
104.1%10/10

Earnings expanding 104.1% YoY

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

P/E RatioValuation
17.3x8/10

Attractively priced relative to earnings

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

BRIA2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.0110/10

Safe zone — low bankruptcy risk

Areas to Watch

BABA4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

Operating MarginProfitability
1.0%3/10

Operating margin of 1.0%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-18.10B2/10

Negative free cash flow — burning cash

BRIA4 concerns · Avg: 2.8/10
Market CapQuality
$38.00M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
2.8%3/10

2.8% margin — thin

Operating MarginProfitability
1.2%3/10

Operating margin of 1.2%

Revenue GrowthGrowth
-10.3%2/10

Revenue declined 10.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, PEG Ratio, EPS Growth. PEG of 0.39 suggests the stock is reasonably priced for its growth.

Bull Case : BRIA

The strongest argument for BRIA centers on Debt/Equity, Altman Z-Score.

Bear Case : BABA

The primary concerns for BABA are Revenue Growth, Operating Margin, Piotroski F-Score.

Bear Case : BRIA

The primary concerns for BRIA are Market Cap, Profit Margin, Operating Margin. Thin 2.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

BABA is growing revenue faster at 2.9% — sustainability is the question.

BRIA generates stronger free cash flow (-5M), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BABA scores higher overall (64/100 vs 32/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

BrilliA Inc

CONSUMER CYCLICAL · APPAREL RETAIL · USA

BrilliA Inc. is an innovative biotechnology company dedicated to enhancing skin health and advancing regenerative medicine through cutting-edge solutions for wound healing. By harnessing proprietary technologies, BrilliA addresses significant unmet medical needs, aiming to improve patient quality of life. With a strong commitment to research and development, the company is well-positioned to transform scientific advancements into effective therapeutic products, solidifying its role as a leader in the dynamic healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?